DRMA
DRMA
NASDAQ · Biotechnology

Dermata Therapeutics Inc

$1.83
+0.06 (+3.39%)
As of Feb 8, 2:31 PM ET ·
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +2,019.1% upside
Low Target $26.82
Average Target $38.78
High Target $44.92
Current Price $1.83
Current
$1.83
Target
$38.78
$26.82 $38.78 avg $44.92
Scenario Analysis
Bear Case
$26.82
1,365.6%
Low target
Base Case
$38.78
+2,019.1%
Avg target
Bull Case
$44.92
+2,354.6%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$36.57
-95.0% from high
52-Week Low
$28.71
+-93.6% from low
Target vs 52W High
$38.78
+6.0% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%